Biopharma

Next Generation Sequencing

With over 400 DNA &1600 RNA NCCN Guideline supported genes, we offer hematologic

and solid tumor molecular profiling as well as liquid biopsy testing, with results typically available in less than 10 days.

NGS Myeloid Profiles

Next generation sequencing (NGS) has proven to be particularly valuable in various hematologic malignancies including the diagnosis, prognosis and treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).

CORE MPN Hotspot Panel (MDS/MPN

Next generation sequencing (NGS) has proven to be particularly valuable in various hematologic malignancies including the diagnosis, prognosis and treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).

CORE Myeloid Profile (MDS/MPN)

DNA expression useful in myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), chronic myeloid monocytic leukemia (CMML) and clonal hematopoiesis of indeterminate potential (CHIP).

CORE Acute Leukemia Expression-Fusion Profile (AML/ALL)

A comprehensive AML/ALL fusion profile evaluation for DNA/RNA that includes IDH1, IDH2, NPM and FLT3 among other genes.

CORE Lymphoma/Fusion-Expression Profile

Comprehensive evaluation of both DNA/RNA gene mutation/expression/fusions found in lymphoma and multiple myeloma (MM) expression.

CORE Liquid Biopsy

Liquid biopsy is a noninvasive alternative for monitoring therapy and early detection of relapse. With over 280 cell free DNA (cfDNA) & >1600 cell free fRNA (cfRNA) genes, a liquid biopsy sample can reliably detect:

  • Chromosomal abnormalities, including gene amplification
  • Fusions
  • Gene expression
  • Alternative splicing
  • HRR
  • HPV/EBV
  • Molecular Residual Disease (MRD)
  • Potential biomarkers through AI enhanced discovery, including those for immunotherapy

Our genomic profiling enables the detection and differentiation of driver and sub-clonal mutations, determines prognosis and identifies targeted therapies for personalized medicine.

CORE Solid Tumor Expression Profile

Comprehensive evaluation of over 400 DNA and 1600 RNA genes including microsatellite instability (MSI), tumor mutation burden (TMB), homologous recombination repair (HRR) mutations and homologous recombination deficiency (HRD).

Hematopathology

We offer comprehensive hematopathology services, including full bone marrow procedures under the supervision of our hematopathologists. Our team of pathologists are American Board Certified in anatomic and clinical pathology, hematopathology, molecular genetics and transfusion medicine to provide a scope of expertise across the most challenging of hematologic malignancies and second opinion requests.

With our 20/20 CORE Evaluation, providers can experience a more streamlined hematopathology approach through the delivery of one concise pathology report. Morphology, flow cytometry, fluorescence in situ hybridization (FISH), cytogenetics, PCR and next generation sequencing (NGS) are ordered by our cancer experts for each patient as medically necessary with summarized results. The subsequent reduction in turnaround time (TAT), need for add-on testing, and elimination of non-integrated reporting provides an opportunity for more efficient patient care and coordination.

CorePath accepts peripheral blood, bone marrow, lymph nodes, fresh tissue biopsies, body fluids, fine needle aspirates and formalin fixed paraffin embedded specimens for hematopathology testing.

Anatomic Pathology

Our team’s board certification and experience in anatomic and clinical pathology allows us to provide subspecialty services for:

  • Surgical Pathology
  • Breast Pathology
  • Gastrointestinal Pathology
  • Urologic Pathology
  • Podiatric Pathology
  • Dermatopathology

In each area, CorePath offers a complement of ancillary technologies to provide diagnostic and prognostic information for clinical support and intervention. Whether special stains, immunohistochemistry, genetic testing, flow cytometry, FISH, PCR or next generation sequencing, CorePath’s testing armamentarium can help deliver answers to guide patient management.

CorePath’s service model accommodates global and TC and PC options for gastrointestinal and urology providers, as well as global and technical or professional component only for flow cytometry testing.

Flow Cytometry

Our multi-color flow cytometry provides exceptionally rapid measurement of multiple characteristics (multi-parametric analysis) of cells suspended in a moving fluid stream as they pass through a series of laser beams. In multi-parametric flow analysis, fluorescently labelled cell components are excited by lasers to emit light at varying wavelengths to efficiently count, sort and analyze thousands of cells per second.

Immunophenotyping of blood, bone marrow or lymph cells to detect various markers or antigens on or within a cell itself, is one of the most common applications for flow cytometry to establish typing of leukemias, lymphomas and other hematopoietic disorders as well as cell subsets present in immunodeficiency diseases. Flow cytometry can also measure new and total synthesized DNA (cell proliferation) for multiple physical and biochemical properties within the same sample.

CorePath’s STAT testing is available for critical cases with same-day flow cytometry.

We offer global, TC and PC flow services.

Cytogenetics (Chromosome Analysis)

Cytogenetics is the study of chromosomes, strands of DNA and protein that contain the genetic information of a cell. Changes in chromosomes, or aberrations, can be hereditary or acquired in the form of rearrangements or altered number (ploidy). Cytogenetics allows for the detection of large DNA changes visible by staining condensed chromosomes in a method known as G-banding, producing a karyotype or visualization of an individual’s complete set of chromosomes. Cytogenetics continues to be the method of choice for facilitating diagnosis, prognosis and treatment options for many types of hematopoietic neoplasms and constitutional disorders.

Fluorescence In Situ Hybridization

Fluorescence in situ hybridization (FISH) is a technique that uses fluorescent probes that bind only to parts of a chromosome with a high degree of sequence complementarity. Fluorescently labeled DNA probes specific to chromosomal regions of interest are used to detect DNA changes on a chromosome. FISH is used to identify submicroscopic numerical abnormalities of chromosomes as well as deletions, duplications, translocations and inversions of certain disease-specific regions beyond the capabilities of classic cytogenetic testing.

FISH testing also allows for the analysis of both metaphase chromosomes in cultured samples, as well as interphase cells in samples where culturing is not possible. In hematopoietic neoplasms, FISH provides rapid detection for aid in diagnosis, prognosis and choice of treatment options.

CorePath’s STAT testing is available for critical cases with 4 to 6 hour PML/RARA FISH results.

Polymerase Chain Reaction (PCR)

Polymerase Chain Reaction (PCR) is an extremely sensitive technology that allows for the rapid amplification of DNA. By generating billions of copies of a gene or specific DNA region, PCR can be used to establish the presence of a very small amount of pathogen or disease in blood, bone marrow or tissue. Like fluorescence in situ hybridization (FISH), PCR does not require actively dividing cells to identify a specific DNA mutation and can routinely detect a change in 1 in 100,000 cells.

In oncology, PCR can be used to isolate and amplify the DNA of tumor suppressor genes and proto-oncogenes and analyze single cells to quantify any combination of DNA, mRNAs and proteins.

Immunohistochemistry/Special Stains

Immunohistochemistry (IHC) is a technology for the selective evaluation of antigens or proteins in tissue cells by exploiting the principle of antibodies binding specifically to antigens. An antibody-antigen interaction is typically characterized by the catalyzation of the antibody conjugate to an enzyme for a color-specific reaction.

IHC staining is widely used in clinical diagnosis and basic research to study abnormal cells such as those found in cancerous tumors and can aid in classifications of neoplasms and determination of site of origin in metastatic tumors. Most recently, IHC immunostaining for PD-L1 expression has been indicated to predict patient response to treatment by PD-L1 inhibitors in specific tumor types.